Sale!

Pemafibrate Extended-Release Tablets 0.4mg (Parmodia XR® / パルモディアXR錠0.4mg)

元の価格は JPY ¥12,300 でした。現在の価格は JPY ¥11,316 です。

Japanese Antihyperlipidemic Agent (Pemafibrate 0.4mg). Oral once-daily extended-release tablet for hyperlipidemia including familial hyperlipidemia. 100 tablets (10 tablets x 10). Mfd. by Kowa Company, Ltd., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥11,316
10 - 19 12% JPY ¥10,824
20 + 18% JPY ¥10,086
SKU: PAR-04-TAB Category:

Description

Product Overview / 商品概要

Pemafibrate Extended-Release Tablets 0.4mg (パルモディアXR錠0.4mg)
Generic: Pemafibrate / ペマフィブラート
Therapeutic Category: Antihyperlipidemic Agent / 高脂血症治療剤
Manufactured by: Kowa Company, Ltd. / 興和株式会社

Composition & Specification / 組成・規格

Active Ingredient: Pemafibrate 0.40mg per tablet / 1錠中 ペマフィブラート 0.40mg
Additives: Microcrystalline cellulose (granules), Hydrated silicon dioxide, Hypromellose, Methacrylic acid copolymer L, Ethylcellulose, Magnesium stearate, D-Mannitol, Microcrystalline cellulose, Crospovidone, Hydroxypropylcellulose, Titanium oxide, Triethyl citrate, Light anhydrous silicic acid, Yellow ferric oxide, Carnauba wax / 結晶セルロース(粒)、含水二酸化ケイ素、ヒプロメロース、メタクリル酸コポリマーL、エチルセルロース、ステアリン酸Mg、D-マンニトール、結晶セルロース、クロスポビドン、ヒドロキシプロピルセルロース、酸化チタン、クエン酸トリエチル、軽質無水ケイ酸、黄色三二酸化鉄、カルナウバロウ
Appearance: Light yellow, round film-coated extended-release tablet. Diameter: 7.6mm, Thickness: 3.9mm, Weight: 168mg. Identification marking: Parmodia XR 0.4
外観: 淡黄色、円形のフィルムコーティング錠(徐放錠)。直径7.6mm、厚さ3.9mm、重量168mg。識別表示: パルモディアXR 0.4

Indications / 効能効果

EN: Hyperlipidemia (including familial hyperlipidemia)
JA: 高脂血症(家族性を含む)

Dosage and Administration / 用法用量

EN: The usual adult dose is 0.2mg of pemafibrate once daily orally. The dose may be increased up to 0.4mg once daily depending on the degree of elevated triglycerides or LDL-cholesterol.
JA: 通常、成人にはペマフィブラートとして1回0.2mgを1日1回経口投与する。ただし、トリグリセライド又はLDL-コレステロール高値の程度により、1回0.4mgを1日1回まで増量できる。

Contraindications / 禁忌

EN: (1) Patients with a history of hypersensitivity to any component of this product; (2) Patients with severe hepatic impairment, liver cirrhosis classified as Child-Pugh B or C, or biliary obstruction; (3) Patients with gallstones; (4) Pregnant women or women who may be pregnant; (5) Patients receiving cyclosporine or rifampicin
JA: (1)本剤の成分に対し過敏症の既往歴のある患者、(2)重篤な肝障害・Child-Pugh分類B又はCの肝硬変のある患者あるいは胆道閉塞のある患者、(3)胆石のある患者、(4)妊婦又は妊娠している可能性のある女性、(5)シクロスポリン・リファンピシンを投与中の患者

Regulatory Information / 規制情報

Approval No.: 30500AMX00128
Sales Started: November 2023 / 2023年11月
Classification Code: 872183
Storage: Store at room temperature / 室温保存
Shelf Life: 3 years / 3年

Packaging / 包装

Main Package (for sale): 100 tablets (10 tablets x 10) / 100錠(10錠×10)
Other Available Packages (by special order): PTP blister: 100 tablets (10 tablets x 10), 500 tablets (10 tablets x 50) / Bulk: 500 tablets (plastic bottle)

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Pemafibrate Extended-Release Tablets 0.4mg (Parmodia XR® / パルモディアXR錠0.4mg)”

メールアドレスが公開されることはありません。 が付いている欄は必須項目です

Export from Japan — Pemafibrate Extended-Release Tablets 0.4mg (Parmodia XR®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.